01:41:25 Europe / Stockholm


2025-02-13 Bokslutskommuniké 2024
2024-11-06 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-07 Kvartalsrapport 2024-Q1
2024-04-25 X-dag ordinarie utdelning ULTI 0.00 NOK
2024-04-24 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-04-21 X-dag ordinarie utdelning ULTI 0.00 NOK
2023-04-20 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-21 X-dag ordinarie utdelning ULTI 0.00 NOK
2022-04-20 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-04-22 X-dag ordinarie utdelning ULTI 0.00 NOK
2021-04-21 Årsstämma 2021
2021-02-17 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-11-11 Extra Bolagsstämma 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-16 X-dag ordinarie utdelning ULTI 0.00 NOK
2020-04-15 Årsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2


ListaOB Match
Ultimovacs är ett norskt läkemedelsbolag. Bolagets affärsinriktning är att utveckla immunoterapier mot diverse cancertillstånd. Forskning och utveckling utgår ifrån egenbaserad teknologisk plattform, där produkterna huvudsakligen vidareutvecklas som vaccin. Störst närvaro återfinns inom Europa och Nordamerika. Bolaget grundades under 2011 och har sitt huvudkontor i Oslo, Norge.
2024-06-01 14:15:00

Oslo, June 1, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage
biotechnology company developing immunotherapeutic cancer vaccines, today
announces that the data from the Phase II clinical trial INITIUM (NCT04382664
(https://clinicaltrials.gov/study/NCT04382664?term=ultimovacs&rank=2)), will be
presented in a poster session at the 2024 ASCO Annual Meeting, taking place May
31 - June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be
found on the 2024 ASCO website: https://meetings.asco.org/abstracts-

INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II
trial evaluating the company's therapeutic cancer vaccine candidate UV1 in
combination with the checkpoint inhibitors ipilimumab and nivolumab as first-
line treatment in unresectable or metastatic malignant melanoma. The trial was
conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and
enrolled 156 patients between June 2020 and July 2022.

The poster presentation features key findings and analyses after minimum 18-
month follow up of the patients in the trial.

Presentation Details:

Abstract Number: LBA9519
Abstract Title: Ipilimumab and nivolumab plus UV1, an anticancer vaccination
against telomerase, in advanced melanoma.

Session Title: Poster Session - Melanoma/Skin Cancers
Poster Board: 303
Date and Time: June 1, 2024, 1:30 PM - 4:30 PM (CT)
Presenter: Paul Lorigan, Professor of Medical Oncology at the University of
Manchester and Investigator in the INITIUM study

Following the presentation, the poster will be available online in the Investor
section of the Company's website: https://ultimovacs.com/


About Ultimovacs

Ultimovacs is a clinical-stage biotechnology leader in novel immunotherapeutic
cancer vaccines with broad applicability. Ultimovacs' lead cancer vaccine
candidate UV1 is directed against human telomerase (hTERT) an antigen which is
present in 85-90% of cancers in all stages of tumor growth. A broad clinical
program, with Phase II trials in five cancer indications enrolling more than
670 patients, aims to demonstrate UV1's impact in combination with other
immunotherapies in multiple cancer types expressing telomerase and where
patients have unmet medical needs. UV1 is universal, off-the-shelf and easy to
use, and is a patented technology owned by Ultimovacs.
In addition, Ultimovacs holds all rights of the proprietary TET technology
platform for any possible future use of formulations in various solid tumor
indications. The Company is listed on Euronext Oslo Stock Exchange (ULTI.OL).

For further information, please contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507

Anne Worsøe, Head of Investor Relations
Email: anne.worsoe@ultimovacs.com (mailto:anne.worsoe@ultimovacs.com)
Phone: +47 90686815

This stock exchange announcement was published by Anne Worsøe, Head of Investor
Relations at Ultimovacs ASA, on June 1, 2024, at 14:15 CET.